- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Challenges With Personalized Medicine
Personalized medicine and diagnostic testing are yet to witness widespread adoption. While there are several reasons for this, David C. Collymore, MD, MBA, would like to sum these challenges into 2 specific buckets. The primary challenge, he believes, are cost and reimbursement. “If insurance companies are not covering the cost of the test, [the test] will be less accessible to the general population. Those that can afford the cost of the testing will go ahead and get it, but the overall population may not have access to it if that’s the case. Reimbursement by managed care is a hurdle for any advancement in healthcare,” Collymore said.
The other challenge is building additional evidence and the need to conduct more studies in a larger patient population. Collymore believes time can help surmount this hurdle. “We need time, we need the tests to be reimbursed, and we need the studies to display evidence of the care. These I think are the 2 main challenges.”
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
